1971 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Alessandro Massimo Gianni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 48 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Open Access
  • Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue

    Ciavarella, S., Vegliante, M. C., Fabbri, M., De Summa, S., Melle, F., Motta, G., De Iuliis, V., Opinto, G., Enjuanes, A., Rega, S., Gulino, A., Agostinelli, C., Scattone, A., Tommasi, S., Mangia, A., Mele, F., Simone, G., Zito, A. F., Ingravallo, G., Vitolo, U. & 19 others, Chiappella, A., Tarella, C., Gianni, A. M., Rambaldi, A., Zinzani, P. L., Casadei, B., Derenzini, E., Loseto, G., Pileri, A., Tabanelli, V., Fiori, S., Rivas-Delgado, A., López-Guillermo, A., Venesio, T., Sapino, A., Campo, E., Tripodo, C., Guarini, A. & Pileri, S. A., Dec 1 2019, In : Annals of Oncology. 30, 12, p. 2015 1 p.

    Research output: Contribution to journalArticle

    Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

    Bruna, R., Benedetti, F., Boccomini, C., Patti, C., Barbui, A. M., Pulsoni, A., Musso, M., Liberati, A. M., Gini, G., Castellino, C., Rossini, F., Ciceri, F., Rota-Scalabrini, D., Stelitano, C., Di Raimondo, F., Tucci, A., Devizzi, L., Zoli, V., Zallio, F., Narni, F. & 15 others, Dondi, A., Parvis, G., Semenzato, G., Lanza, F., Perrone, T., Angrilli, F., Billio, A., Gueli, A., Mantoan, B., Rambaldi, A., Massimo Gianni, A., Corradini, P., Passera, R., Ladetto, M. & Tarella, C., Jan 1 2019, In : Haematologica. 104, 11, p. 2241-2248 8 p.

    Research output: Contribution to journalArticle

    Open Access
  • A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

    Trnĕný, M., Verhoef, G., Dyer, M. J., Ben Yehuda, D., Patti, C., Canales, M., Lopez, A., Awan, F. T., Montgomery, P. G., Janikova, A., Barbui, A. M., Sulek, K., Terol, M. J., Radford, J., Guidetti, A., Di Nicola, M., Siraudin, L., Hatteville, L., Schwab, S., Oprea, C. & 1 others, Gianni, A. M., Aug 2018, In : Haematologica. 103, 8, p. 1351-1358 8 p.

    Research output: Contribution to journalArticle

  • Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells

    Satta, A., Mezzanzanica, D., Caroli, F., Frigerio, B., Di Nicola, M., Kontermann, R. E., Iacovelli, F., Desideri, A., Anichini, A., Canevari, S., Gianni, A. M. & Figini, M., 2018, In : mAbs. 10, 7, p. 1084-1097 14 p.

    Research output: Contribution to journalArticle